Reaction

Infusion Site Nodule reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 889 reports · 40 co-occurring drugs

As of the last recalculation, Infusion Site Nodule appears in 889 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is KETOPROFEN (PRR 112.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ketoprofen	59	112.7	113.2
Amitriptyline Hydrochloride	51	72.1	72.3
Treprostinil	270	71.9	72.1
Lidocaine Hydrochloride	104	45.6	45.7
Sildenafil Powder,	51	35.5	35.6
Epinephrine	86	33.9	34.0
0Xygen	65	33.3	33.3
Oxygen	65	33.3	33.3
Human Immunoglobulin G	28	32.8	32.8
Lidocaine	73	31.8	31.9
Sildenafil	72	31.6	31.6
Clonidine	64	31.4	31.5
Diphenhydramine	75	30.3	30.3
Macitentan	78	28.8	28.8
Amantadine	17	26.2	26.2
Lidicaine	49	24.8	24.8
Burn Relief	49	24.8	24.8
Lidocaine Hydrochloride And Epinephrine	49	24.7	24.7
Lidocaine, Menthol	49	24.4	24.4
Lidocaine Hydrochloride And Epinephrine Bitartrate	49	22.7	22.7
Tadalafil	87	22.4	22.5
Lidocaine 4%	49	22.2	22.2
Adrenalinum	37	21.7	21.8
Sildenafil Citrate	100	20.6	20.6
Rasagiline Mesylate	9	19.1	19.1
Rotigotine	11	18.0	18.0
Sodium Chloride Tablet	52	17.5	17.5
Sodium Chloride Tablets	52	17.5	17.5
Pramipexole	11	17.0	17.0
Sodium Chloride	52	16.3	16.3
Cetirizine Hcl	6	15.4	15.4
Bumetanide	17	15.3	15.4
Buspirone Hydrochloride	7	15.0	15.0
Azelastine	11	14.5	14.5
Ambrisentan	71	14.4	14.4
Riociguat	19	13.9	13.9
Levodopa	6	11.7	11.7
Carbidopa And Levodopa	22	11.1	11.1
Bosentan	23	10.9	10.9
Pimavanserin Tartrate	6	2.6	2.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.